GlassScriptPhysician profile
Ashlee N Russo
NPI 1861718256
$60,631.79
in general payments reported to CMS, 2019-2025
39 companies · $50K in 2025
The $50K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,337 · 2020: $478 · 2021: $488 · 2022: $1,179 · 2023: $2,234 · 2024: $2,160 · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Food and Beverage: $7,344 · Travel and Lodging: $3,910 · Consulting Fee: $3,170 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,565.80 |
| Food and Beverage | $7,344.18 |
| Travel and Lodging | $3,909.71 |
| Consulting Fee | $3,170.00 |
| Education | $159.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $27,912.69 | 2020-2025 | Dupixent |
| Genzyme Corporation | $19,164.89 | 2022-2025 | |
| Insmed, INC. | $4,448.75 | 2019-2025 | Brinsupri, Arikayce |
| Astrazeneca Pharmaceuticals LP | $2,176.80 | 2019-2025 | Tezspire, Fasenra, Imfinzi |
| United Therapeutics Corporation | $1,680.12 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Noah Medical Corporation | $1,592.94 | 2023-2025 | Galaxy |
| Glaxosmithkline, LLC. | $936.91 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.95 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $296.12 | 2019-2025 | Opsumit, Uptravi |
| Ethicon INC. | $252.17 | 2019-2022 | |
| Amgen INC. | $213.77 | 2021-2024 | Tezspire |
| Merck Sharp & Dohme LLC | $205.40 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Grifols USA, LLC | $185.01 | 2019-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $124.98 | 2024 | |
| Genentech USA, INC. | $120.31 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.